Biologic Predictors of Clinical Improvement in Rituximab-Treated Refractory Myositis

BMC Musculoskeletal Disorders - United Kingdom
doi 10.1186/s12891-015-0710-3
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Biomarkers for Predicting Clinical Relapse in Refractory Pemphigus Patients Treated With Rituximab

Pathology
Forensic MedicinePathology
2020English

Severe Refractory Paraneoplastic Mucous Membrane Pemphigoid Successfully Treated With Rituximab

Frontiers in Medicine
Medicine
2019English

Rituximab for Refractory Wegener's Granulomatosis

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2006English

The Clinical Characteristics and Predictors of Refractory Mycoplasma Pneumoniae Pneumonia in Children

PLoS ONE
Multidisciplinary
2016English

Steroid Refractory Autoimmune Haemolytic Anaemia Secondary to Sarcoidosis Successfully Treated With Rituximab and Mycophenolate Mofetil

Case Reports in Hematology
2016English

Identifying Demographic, Social and Clinical Predictors of Biologic Therapy Effectiveness in Psoriasis: A Multicentre Longitudinal Cohort Study

British Journal of Dermatology
DermatologyMedicine
2018English

Rituximab Induces Remission in Refractory HCV Associated Cryoglobulinaemic Vasculitis

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2003English

NK Cell Count as Predictor of Clinical Response in Patients With Rheumatoid Arthritis Treated With Rituximab

Biologics: Targets and Therapy
OncologyImmunologyGastroenterologyPharmacologyRheumatologyAllergy
2012English

Novel Use of Rituximab in Hypersensitivity Pneumonitis Refractory to Conventional Treatment

Thorax
PulmonaryRespiratory Medicine
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy